Vertex Pharmaceuticals reports $2.99 billion revenue for quarter ended March 31, 2026, up 7.8%

ยท VRTX

Vertex Pharmaceuticals reported revenue of $2.99 billion for the quarter ended March 31, 2026, an increase of 7.8% from the same quarter a year earlier ($2.77 billion).

For the same period it posted net income of $1.03 billion, up 59.6%, or $4.02 per diluted share (2.49 a year earlier).

That is a net margin of 34.5%.

On Sanad's AAOIFI Standard 21 screen, Vertex Pharmaceuticals is currently compliant: interest-bearing debt is 3.3% of market capitalisation (limit 30%), and impure income is 4.1% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Vertex Pharmaceuticals news